The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine
prostate cancer (t-SCNC) are not well characterized in the era of modern androgen receptor …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Background PROpel met its primary endpoint showing statistically significant improvement
in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Background Abiraterone acetate plus prednisolone improves survival in men with relapsed
prostate cancer. We assessed the effect of this combination in men starting long-term …

Background Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus
prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the …

Background Abiraterone acetate plus prednisone and enzalutamide are both used for the
treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best …

Prostate cancer is the most commonly diagnosed cancer affecting men in the United States.
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …

Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer
(CRPC) is associated with sustained AR signaling, including through alternative splicing of …